跳至主要内容
临床试验/NCT06710249
NCT06710249招募中2 期

Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema

Peter Siesjö1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年1月27日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20
试验地点
1
主要终点
Change of neurological symptoms

研究概览

简要总结

The objective of this clinical trial is to explore the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, and SPC® flakes , hydrothermically processed oats, on cerebral edema with clinical symptoms in participants with brain tumors.

The primary questions the trial seeks to answer are:

  • Can Salovum® and SPC® flakes have effect on clinical symptoms of tumor-induced cerebral edema?
  • Can Salovum® and SPC® flakes induce regression of radiological edema in tumor-induced cerebral edema Additionally, the study will investigate the impact of Salovum® and SPC® flakes in steroid refractory, steroid naïve cerebral edema and type of barin tumor

Researchers will:

Evaluate edema change from baseline by MRI after 14 days Evaluate neurological and cognitive symptoms Register dose of steroid medications

Participants will:

  • Ingest Salovum® 11g three times daily for 14 days, thereafter tapered during 14 days
  • Ingest SPC® flakes 1g/kg daily from day 7

详细描述

Background and Rationale Both primary and secondary brain tumors malignant but also benign meningiomas can induce cerebral edema . The edema can cause several nerurologic and cognitive symptoms which affect both performance and quality of life. Cerebral edema can be treated with high dose corticosteroids but witj substantial side effects. Alternative less toxic therapies are warranted.

Antisecretory factor (AF) is a crucial 41 kDa endogenous protein initially identified for its ability to inhibit experimental diarrhea. The active amino-terminal segment of AF has been synthesized into a 16-amino acid peptide (AF-16) and utilized in animal studies. Salovum®, a product based on the egg yolk powder B221®, contains high levels of AF and is classified as a "food for special medical purposes" by the European Food Safety Agency. It is available over-the-counter in Swedish pharmacies. Specially processed cereals (SPC®) have been shown to induce circulating AF derived peptides after ingestion.

Many tumors, including glioblastoma, exhibit higher interstitial fluid pressure (IFP) than surrounding tissues, potentially hindering chemotherapy penetration in systemic treatments and possibly increasing excretion during intratumoral treatments.

In head injury models, AF has been effective in reducing elevated intracranial pressure and improving functional outcomes. Similarly, AF has demonstrated a significant reduction in intracranial pressure and increased survival rates in an experimental model of herpes encephalitis. Preliminary results from our studies indicate that treatment with antisecretory factor in patients with severe traumatic head injuries reduces intracranial pressure and improves treatment outcomes. Since Salovum® is not classified as a drug, clinical trials have only required ethics approval.

AF is an endogenous protein, and no antibody formation has been observed when administered to humans. Despite being administered to hundreds of patients, no side effects have been reported. Egg yolk allergy is a contraindication, though no cases of triggered allergies have been documented.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 18-79 years
  • •Known or radiologically suspected primary or secondary brain tumor (suspected metastasis, meningioma, glioma, etc.) with surrounding edema causing clinical signs
  • •WHO ECOG performance status 0-2
  • •Planned or started cortisone treatment
  • •Ability to provide informed consent

排除标准

  • •Egg yolk allergy
  • •Midline shift >5mm
  • •Epilepsy as sole symptom from the cerebral edema

研究组 & 干预措施

Salovum/SPC flakes

Experimental

干预措施: Salovum/SPC flakes (Dietary Supplement)

结局指标

主要结局

Change of neurological symptoms

时间窗: 28 days

To investigate whether Salovum® and SPC® flakes can change neurological symptoms in participants with tumor induced cerebral oedema as measured by the neurologic assessment in neurooncology (NANO) scale (range 0-23, 0 best-23 worst)

次要结局

  • Change of cerebral edema(28 days)

研究者

发起方
Peter Siesjö
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Peter Siesjö

Consultant, MD, PhD

Skane University Hospital

研究点 (1)

Loading locations...

相似试验